In 126 patients with atrial septal defect, the novel ReAces occluder was noninferior to a traditional Amplatzer-like occluder for complete closure at 12 months (98.4% vs 98.4%); one device dislodgement occurred with ReAces. Migraine disability scores were lower at 1 month.
RCTn = 126
Fang et al. Comparison of a Novel Occluder Versus Traditional Occluder in Atrial Septal Defect: A Randomized Trial